Unknown

Dataset Information

0

Vaccination targeting a surface sialidase of P. acnes: implication for new treatment of acne vulgaris.


ABSTRACT:

Background

Acne vulgaris afflicts more than fifty million people in the United State and the severity of this disorder is associated with the immune response to Propionibacterium acnes (P. acnes). Systemic therapies for acne target P. acnes using antibiotics, or target the follicle with retinoids such as isotretinoin. The latter systemic treatment is highly effective but also carries a risk of side effects including immune imbalance, hyperlipidemia, and teratogenicity. Despite substantial research into potential new therapies for this common disease, vaccines against acne vulgaris are not yet available.

Methods and findings

Here we create an acne vaccine targeting a cell wall-anchored sialidase of P. acnes. The importance of sialidase to disease pathogenesis is shown by treatment of a human sebocyte cell line with recombinant sialidase that increased susceptibility to P. acnes cytotoxicity and adhesion. Mice immunized with sialidase elicit a detectable antibody; the anti-sialidase serum effectively neutralized the cytotoxicity of P. acnes in vitro and P. acnes-induced interleukin-8 (IL-8) production in human sebocytes. Furthermore, the sialidase-immunized mice provided protective immunity against P. acnes in vivo as this treatment blocked an increase in ear thickness and release of pro-inflammatory macrophage inflammatory protein (MIP-2) cytokine.

Conclusions

Results indicated that acne vaccines open novel therapeutic avenues for acne vulgaris and other P. acnes-associated diseases.

SUBMITTER: Nakatsuji T 

PROVIDER: S-EPMC2212713 | biostudies-literature | 2008 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Vaccination targeting a surface sialidase of P. acnes: implication for new treatment of acne vulgaris.

Nakatsuji Teruaki T   Liu Yu-Tsueng YT   Huang Cheng-Po CP   Zouboulis Christos C CC   Gallo Richard L RL   Huang Chun-Ming CM  

PloS one 20080206 2


<h4>Background</h4>Acne vulgaris afflicts more than fifty million people in the United State and the severity of this disorder is associated with the immune response to Propionibacterium acnes (P. acnes). Systemic therapies for acne target P. acnes using antibiotics, or target the follicle with retinoids such as isotretinoin. The latter systemic treatment is highly effective but also carries a risk of side effects including immune imbalance, hyperlipidemia, and teratogenicity. Despite substantia  ...[more]

Similar Datasets

| S-EPMC3388602 | biostudies-literature
| S-EPMC2772209 | biostudies-literature
| S-EPMC2855893 | biostudies-literature
| S-EPMC4084940 | biostudies-literature
| S-EPMC5524737 | biostudies-other
| S-EPMC5527720 | biostudies-other
| S-EPMC4043801 | biostudies-other
| S-EPMC9254491 | biostudies-literature
| S-EPMC3888247 | biostudies-literature
| S-EPMC10486177 | biostudies-literature